Veracyte/$VCYT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Veracyte
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
Ticker
$VCYT
Sector
Primary listing
Employees
824
Headquarters
Website
Veracyte Metrics
BasicAdvanced
$2.5B
94.91
$0.34
1.97
-
Price and volume
Market cap
$2.5B
Beta
1.97
52-week high
$47.32
52-week low
$22.61
Average daily volume
1.3M
Financial strength
Current ratio
5.425
Quick ratio
4.861
Long term debt to equity
3.622
Total debt to equity
4.148
Interest coverage (TTM)
20,398.50%
Profitability
EBITDA (TTM)
62.782
Gross margin (TTM)
70.54%
Net profit margin (TTM)
5.50%
Operating margin (TTM)
8.51%
Effective tax rate (TTM)
9.09%
Revenue per employee (TTM)
$580,000
Management effectiveness
Return on assets (TTM)
1.98%
Return on equity (TTM)
2.24%
Valuation
Price to earnings (TTM)
94.91
Price to revenue (TTM)
5.171
Price to book
2.05
Price to tangible book (TTM)
7.11
Price to free cash flow (TTM)
29.507
Free cash flow yield (TTM)
3.39%
Free cash flow per share (TTM)
1.08
Growth
Revenue change (TTM)
19.91%
Earnings per share change (TTM)
-146.16%
3-year revenue growth (CAGR)
21.32%
10-year revenue growth (CAGR)
26.64%
3-year earnings per share growth (CAGR)
-21.21%
10-year earnings per share growth (CAGR)
-13.39%
What the Analysts think about Veracyte
Analyst ratings (Buy, Hold, Sell) for Veracyte stock.
Bulls say / Bears say
Veracyte’s Decipher prostate cancer test posted its thirteenth straight quarter with over 25% year-over-year volume growth, rising 28% in Q2 2025, demonstrating continued strong demand for the company’s key test (Reuters).
Total revenue for Q2 2025 grew 14% year-over-year to $130.2 million, surpassing analyst estimates. As a result, Veracyte raised its full-year testing revenue guidance to $477 million–$483 million and issued total revenue guidance of $496 million–$504 million (Reuters).
Adjusted EBITDA in Q2 2025 jumped 49% year-over-year to $35.8 million, accounting for 27.5% of revenue versus 21.0% last year, indicating enhanced operating efficiency and wider margins (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.
Veracyte Financial Performance
Revenues and expenses
Veracyte Earnings Performance
Company profitability
Veracyte News
AllArticlesVideos
Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
Business Wire2 weeks ago
Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
Business Wire2 weeks ago
Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test
Business Wire3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Veracyte stock?
Veracyte (VCYT) has a market cap of $2.5B as of September 13, 2025.
What is the P/E ratio for Veracyte stock?
The price to earnings (P/E) ratio for Veracyte (VCYT) stock is 94.91 as of September 13, 2025.
Does Veracyte stock pay dividends?
No, Veracyte (VCYT) stock does not pay dividends to its shareholders as of September 13, 2025.
When is the next Veracyte dividend payment date?
Veracyte (VCYT) stock does not pay dividends to its shareholders.
What is the beta indicator for Veracyte?
Veracyte (VCYT) has a beta rating of 1.97. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.